1st Alpine Winter Conference on Medicinal and Synthetic Chemistry

Oral Communications have been selected!

Abstract submission for poster is still open. Deadline is November 20, 2017

Spread the word with #AlpineWinterConference

Confirmed Speakers


Keynote Speakers

 Erick M. CARREIRA
Erick M. CARREIRA
ETH ZÜRICH, Zürich, Switzerland

Recent Developments in Strategies and Tactics Towards the Synthesis of Complex Secondary Metabolites as Enabling Tools for the Study of Biology and Medicine

 Benjamin CRAVATT
Benjamin CRAVATT
THE SCRIPPS RESEARCH INSTITUTE, La Jolla, United States
Read more

Activity-based proteomics – Protein and Ligand Discovery on a Global Scale

 Anabella VILLALOBOS
Anabella VILLALOBOS
BIOGEN, Cambridge, United States
Read more

Novel Approaches in the Design of CNS Drug Candidates and PET Ligands

Addressing Preclinical Toxicity – Approaches and Lessons Learned

 Peter DRAGOVICH
Peter DRAGOVICH
GENENTECH INC., San Francisco, United States
Read more

Mechanism-Based Toxicities Associated With NAMPT Inhibition and Related Mitigation Strategies

 Martin PETTERSSON
Martin PETTERSSON
PFIZER, Cambridge, United States
Read more

Small Structural Changes Leading to Major Impact on Safety: Developing Safety Strategies in Medicinal Chemistry (OC2)

 Axel PÄHLER
Axel PÄHLER
F. HOFFMANN-LA ROCHE, Basel, Switzerland
Read more

Overcoming Drug Bioactivation in Lead Optimization: Case Studies

 Douglas THOMSON
Douglas THOMSON
CELLZOME GMBH, Heidelberg, Germany
Read more

Utilizing in Depth Understanding of a Molecules Off Target Profile to Tailor Clinical and Preclinical Safety Assessments

Advances in Lead Generation

 Monika ERMANN
Monika ERMANN
EVOTEC LTD, Oxfordshire, United Kingdom
Read more

A Chemist’s Guide to Modern Phenotypic Drug Discovery

 Koen HEKKING
Koen HEKKING
MERCACHEM B.V. , Nijmegen, The Netherlands
Read more

CDK8 Inhibitors with Pre-Engineerd Long Residence Time, Exhibiting Efficacy in Tumor Xenograft Models (OC03)

 Eva Maria MARTIN
Eva Maria MARTIN
ELI LILLY, Madrid, Spain
Read more

ADAS (Affinity Directed Automated Synthesis): A New Technology to Accelerate Lead Generation

 Sanne SCHRODER GLAD
Sanne SCHRODER GLAD
NUEVOLUTION A/S, Copenhagen, Denmark
Read more

From Multiple Hit Series to (Pre)Clinical Candidates Using DNA Encoded Library Technology

Advances in Synthetic Methods

 Varinder K. AGGARWAL
Varinder K. AGGARWAL
UNIVERSITY OF BRISTOL, Bristol, United Kingdom
Read more

Assembly Line Synthesis

 Thorsten BACH
Thorsten BACH
TECHNISCHE UNIVERSITÄT MÜNCHEN, Garching, Germany
Read more

Photochemical Reactions en route to Structurally Complex Molecules

 Ilan MAREK
Ilan MAREK
ISRAEL INSTITUTE OF TECHNOLOGY, Haifa, Israel
Read more

Small Ring Chemistry

Alternative Modalities

 Niall ANDERSON
Niall ANDERSON
GLAXOSMITHKLINE, Hertfordshire, United Kingdom

Proteolysis Targetting Chimera: A New Frontier in Medicinal Chemistry (OC05)

 Kerry BENENATO
Kerry BENENATO
MODERNA THERAPEUTICS, Cambridge, United States

Messenger RNA as a Novel Therapeutic Approach

 David TELLERS
David TELLERS
MERCK & CO. INC (MSD), West Point, United States
Read more

Discovery Chemistry Modalities: Chemistry on the Macromolecular Scale

 Eric VALEUR
Eric VALEUR
ASTRAZENECA, Västra Frölunda, Sweden
Read more

New Modalities for Challenging Targets in Drug Discovery

Challenges and Opportunities in Fragment Based Drug Discovery

 Tom HEIGHTMAN
Tom HEIGHTMAN
ASTEX THERAPEUTICS, Cambridge, United Kingdom

Drug Discovery for Challenging Targets by X-ray Crystallographic Fragment Screening

 Rod HUBBARD
Rod HUBBARD
UNIVERSITY OF YORK & VERNALIS, Cambridge, United Kingdom
Read more

The Impact of Fragments on Drug Discovery

 Mairi SIME
Mairi SIME
BEATSON INSTITUTE FOR CANCER RESEARCH, Bearsden Glasgow , United Kingdom
Read more

Fragment Based Discovery of Small Molecule MRCK Inhibitors

Chemical Biology in Drug and Target Discovery

 Gonçalo BERNARDES
Gonçalo BERNARDES
INSTITUTO DE MEDICINA MOLECULAR, LISBON, PORTUGAL & UNIVERSITY OF CAMBRIDGE, Cambridge, United Kingdom
Read more

Chemical Physiology of Antibody Conjugates and Natural Products (OC04)

 Kai JOHNSSON
Kai JOHNSSON
SWISS FEDERAL INSTITUTE OF TECHNOLOGY IN LAUSANNE (EPFL), Lausanne, Switzerland
Read more

Biosensors for Measuring Metabolite and Drug Concentrations in Living Cells

Late Stage Functionalization

 Nicolai CRAMER
Nicolai CRAMER
ECOLE POLYTECHNIQUE FÉDÉRALE DE LAUSANNE, Lausanne, Switzerland

Title to be announced

 Darren J. DIXON
Darren J. DIXON
UNIVERSITY OF OXFORD, Oxford, United Kingdom
Read more

Catalytic Approaches to Simplifying Synthesis

 Matthew GAUNT
Matthew GAUNT
UNIVERSITY OF CAMBRIDGE, Cambridge, United Kingdom

Read more

Title to be announced

 Mark LAUTENS
Mark LAUTENS
UNIVERSITY OF TORONTO, Toronto, ON, Canada

Read more

Synthetic Routes to Oxindoles via Metal Catalysis (OC06)

Drug Discovery Tales

 Holger MONENSCHEIN
Holger MONENSCHEIN
TAKEDA CALIFORNIA, INC, San Diego, United States

Discovery of Tak-041: A Potent and Selective Gpr139 Agonist for the Treatment of Negative Symptoms Associated with Schizophrenia

 Jean QUANCARD
Jean QUANCARD
NOVARTIS PHARMA, Basel, Switzerland
Read more

Discovery of Allosteric Malt1 Protease Inhibitors with High in Vivo Efficacy (OC08)


EFMC Sponsored Event

Silver Sponsor

Bronze Sponsors

Sponsors

Media Partner

Copyright 2017 LD Organisation  |  rue Michel de Ghelderode 33/02 B-1348  Louvain-la-Neuve (Belgium)  Tel. +32 10 454777  |   |  VAT: BE 0464819842
Developed and powered by Antalys